Opendata, web and dolomites

RESHAPE SIGNED

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RESHAPE project word cloud

Explore the words cloud of the RESHAPE project. It provides you a very rough idea of what is the project "RESHAPE" about.

fih    science    curative    ec    specificity    transdisciplinarity    imbalance    cas9    patients    overcome    reshape    regenerative    enhanced    transplant    transplantation    antigen    data    academic    performed    tissue    cell    gene    pioneers    platforms    options    graft    health    longtrack    stability    host    immunity    stem    transform    game    trials    translation    biomarker    combat    diseases    disease    versus    first    allotransplantation    rejection    1st    medicine    tested    hsc    record    economic    medicinal    generation    transfer    clinical    backgrounds    vitro    function    recipient    allografts    undesired    changer    reaction    limitations    crispr    studies    vivo    presently    treg    basic    adoptive    supports    treatment    biotech    atmp    conditioning    hematopoietic    option    models    suffering    therapy    overcoming    therapeutic    limited    inflammation    broad    immune    entities    encouraging    organ    triple    members    accompanied    care    human    proven    technologies    regulatory    functional    cells    preclinical   

Project "RESHAPE" data sheet

The following table provides information about the project.

Coordinator
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 

Organization address
address: Chariteplatz 1
city: BERLIN
postcode: 10117
website: www.charite.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 13˙137˙396 €
 EC max contribution 13˙137˙396 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) coordinator 4˙137˙775.00
2    CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES FR (NANTES) participant 2˙023˙468.00
3    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 1˙998˙550.00
4    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 1˙548˙050.00
5    TISSUSE GMBH DE (BERLIN) participant 1˙026˙250.00
6    CELL THERAPY CATAPULT LIMITED UK (LONDON) participant 975˙625.00
7    TXCELL FR (VALBONNE) participant 502˙077.00
8    NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN DE (REUTLINGEN) participant 499˙500.00
9    INNOVATION ACTA S.R.L. IT (ROMA) participant 426˙100.00

Map

 Project objective

Adoptive transfer of regulatory T cells (Treg) is a promising new therapeutic option to reshape undesired intra-tissue immune imbalance in immune-related disease entities. It supports long-term function of allografts and use of Advanced Therapy Medicinal Products (ATMP) by overcoming the challenge of unwanted immune reaction by the recipient of the ATMP. Therefore, adoptive Treg therapy is a potential game changer in health care, particularly in immune diseases, organ & hematopoietic stem cell (HSC) transplantation, and regenerative medicine, including gene therapy. Based on the Triple-T concept - Transdisciplinarity, Technology, Translation - the major goal of RESHAPE is to transform the treatment of patients suffering from undesired immunity/inflammation, who presently have limited curative treatment options, by applying novel Treg approaches that overcome the limitations of 1st generation Treg product developments. Members of the consortium, with academic & biotech backgrounds, are pioneers in the development of Treg therapy from basic science to very recent encouraging First-In-Human (FIH) clinical trials of the 1st generation Treg products. They have a longtrack record of collaboration, including in EC-funded projects. The first clinical trials were performed to combat organ transplant rejection and Graft-versus-Host-Disease. However, promising preclinical studies offer a broad application field of Treg therapy beyond allotransplantation. Based on our preclinical & clinical data, we have identified several opportunities for improving Treg therapy, such as enhanced antigen specificity & functional stability, and recipient conditioning, that will be addressed by RESHAPE. The next-generation Treg products, developed by advanced technologies including CRISPR/Cas9, will be tested on platforms applying new methods for cell characteristics in both in vivo /in vitro models, and finally proven in FIH-clinical trials accompanied by biomarker and health economic studies

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESHAPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RESHAPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More